- Home
- RNXT vs EDAP Comparison
RNXT vs EDAP Comparison
Compare RNXT & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- EDAP
- Stock Information
- Founded
- RNXT 2012
- EDAP 1979
- Country
- RNXT United States
- EDAP France
- Employees
- RNXT N/A
- EDAP N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RNXT Health Care
- EDAP Health Care
- Exchange
- RNXT Nasdaq
- EDAP Nasdaq
- Market Cap
- RNXT 44.6M
- EDAP 46.7M
- IPO Year
- RNXT 2021
- EDAP 1997
- Fundamental
- Price
- RNXT $1.25
- EDAP $2.75
- Analyst Decision
- RNXT Strong Buy
- EDAP Buy
- Analyst Count
- RNXT 2
- EDAP 3
- Target Price
- RNXT $7.50
- EDAP $8.50
- AVG Volume (30 Days)
- RNXT 339.0K
- EDAP 161.3K
- Earning Date
- RNXT 08-14-2025
- EDAP 08-28-2025
- Dividend Yield
- RNXT N/A
- EDAP N/A
- EPS Growth
- RNXT N/A
- EDAP N/A
- EPS
- RNXT N/A
- EDAP N/A
- Revenue
- RNXT $662,000.00
- EDAP $74,008,221.00
- Revenue This Year
- RNXT $2,988.37
- EDAP N/A
- Revenue Next Year
- RNXT $300.60
- EDAP N/A
- P/E Ratio
- RNXT N/A
- EDAP N/A
- Revenue Growth
- RNXT N/A
- EDAP 1.56
- 52 Week Low
- RNXT $0.75
- EDAP $1.21
- 52 Week High
- RNXT $1.69
- EDAP $3.77
- Technical
- Relative Strength Index (RSI)
- RNXT 62.94
- EDAP 87.37
- Support Level
- RNXT $0.90
- EDAP $1.30
- Resistance Level
- RNXT $0.95
- EDAP $1.48
- Average True Range (ATR)
- RNXT 0.08
- EDAP 0.22
- MACD
- RNXT 0.03
- EDAP 0.16
- Stochastic Oscillator
- RNXT 86.54
- EDAP 83.30
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.